Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. (OTCQB: AINMF) generates news centered on the application of explainable artificial intelligence to pharmaceutical clinical trials. The company regularly reports on contracts with global pharmaceutical and biopharmaceutical companies, collaborations with research institutions, scientific publications, and regulatory-science interactions related to its NetraAI platform.
News updates often highlight new agreements in which NetraAI is applied to late-stage clinical studies, including Phase III trials in psychiatric indications. These announcements describe how NetraAI is used to identify responder and non-responder subgroups, analyze treatment and placebo-response patterns, and support interpretation of complex trial outcomes. The company also reports on expansions of existing relationships through master services agreements and the growth of its contract backlog for NetraAI services.
Another recurring theme in NetraMark’s news is its scientific and academic engagement. The company has announced acceptance of a peer-reviewed NetraAI study in npj Digital Medicine, presentations at CNS-focused clinical trial and neuropsychopharmacology conferences, and research collaborations in areas such as major depressive disorder, schizophrenia, and glioblastoma. These items describe how NetraAI is deployed within secure research environments to analyze clinical, genetic, epigenetic, and proteomic datasets and to uncover explainable patient subpopulations.
Regulatory-science news includes coverage of NetraMark’s Critical Path Innovation Meeting with the U.S. Food and Drug Administration, where the scientific aspects of NetraAI’s enrichment methodology were discussed. Financing news, such as private placement offerings, provides context on how the company plans to fund advancement and commercialization of NetraAI and support ongoing and prospective biopharmaceutical engagements.
Investors and observers who follow AINMF news can therefore expect updates on commercial contracts, research collaborations, peer-reviewed publications, regulatory-science interactions, and capital-raising activities, all tied to the development and deployment of NetraAI in pharmaceutical clinical development.
NetraMark (OTCQB: AINMF) appointed Dr. Panteli Theocharous as Fractional Chief Medical Officer on May 4, 2026, to support global deployment of the NetraAI platform. Dr. Theocharous will continue his roles at Worldwide Clinical Trials and will advise on clinical strategy, trial design, patient stratification, and regulatory translation. Outgoing CMO Dr. Larry Alphs will remain as an advisor to ensure continuity.
NetraMark (OTCQB: AINMF; TSX: AIAI) will open trading on the Toronto Stock Exchange on May 5, 2026 at the market open ceremony. Senior management will perform the market open at 9:30 AM ET, and the event will be livestreamed.
NetraMark develops the NetraAI platform for clinical trial optimization and patient stratification, and the market open highlights ongoing investor engagement and recent collaborations in oncology and other therapeutic areas.
NetraMark (OTCQB: AINMF) highlights its NetraAI platform as a purpose-built analytics solution to support psychedelic and CNS clinical trials amid recent U.S. executive action. The company cites peer‑reviewed validation in npj Digital Medicine and Frontiers in Pharmacology, ongoing psychedelic trial programs, and an emphasis on explainable, regulator‑ready subgroup identification.
NetraMark stresses that policy momentum does not lower regulatory evidence standards and positions NetraAI to improve patient stratification, signal detection, and trial design for small, heterogeneous datasets.
NetraMark (OTCQB: AINMF) commented on the U.S. Executive Order of April 18, 2026 to accelerate treatments for serious mental illness, including investigational psychedelic programs. NetraMark urged rigorous, regulatory‑grade trial design and highlighted its NetraAI platform for explainable subgroup analytics to improve signal detection in CNS trials.
NetraMark (OTCQB: AINMF) announced a peer-reviewed article published April 9, 2026, in Frontiers in Pharmacology proposing a testable hypothesis linking psychedelics, calcium/phosphate biology, and possible spin-dependent processes.
The paper, led by NetraMark founders, frames inter-individual treatment variability as structured biological heterogeneity and outlines a translational pathway to biomarker-guided, explainable-AI trial design aligned with NetraAI platform capabilities.
NetraMark (OTCQB: AINMF) announced a strategic research collaboration with Fondazione per la Medicina Personalizzata to analyze the ROME Phase II oncology trial dataset (NCT04591431) using NetraMark's NetraAI platform. The ROME trial randomized 400 patients and reported improved overall response rate and progression-free survival for tailored treatment versus standard of care.
The collaboration will seek Model-Derived Subgroups and evaluate endpoints including PFS, ORR, OS, time to treatment failure, and safety, subject to data availability and joint governance.
NetraMark (OTCQB: AINMF) presented a poster at the AD/PD 2026 conference (March 17-21) showing that its explainable AI, NetraAI, identified two treatment-responsive subgroups in the Phase 3 A4 solanezumab dataset.
Findings include biologically interpretable subgroups with preserved limbic/temporal network integrity and effect sizes up to Cohen’s d 1.52, suggesting AI-enabled precision enrichment may reveal masked therapeutic signals.
NetraMark (OTCQB: AINMF) signed a contract with a leading global biopharmaceutical company to analyze data from a Phase 2 depression clinical trial using its NetraAI platform. The engagement aims to identify patient subpopulations, evaluate treatment response patterns, and inform future study design with AI-driven precision insights.
NetraAI applies a dynamical systems framework to multi-dimensional, small clinical datasets to stratify high-effect-size cohorts and translate findings into clinically meaningful trial enrichment criteria.
NetraMark (OTCQB: AINMF) closed the second and final tranche of a non-brokered private placement on Feb 18, 2026, issuing 390,000 Units at $1.00 each for $390,000. The Offering raised aggregate gross proceeds of $3.5 million via 3,500,000 Units.
Each Unit includes one common share and one-half warrant; each whole warrant is exercisable at $1.35 for two years. Post-closing, there are 92,223,699 common shares outstanding. Securities are subject to a four-month-and-one-day hold ending June 19, 2026, and are not registered in the United States.
NetraMark (AIAI / OTCQB: AINMF) announced it will uplist to the Toronto Stock Exchange. The Company will voluntarily delist from the Canadian Securities Exchange effective close of market Feb 17, 2026 and commence TSX trading at market open Feb 18, 2026 under symbol AIAI.
The Common Shares will remain listed on the OTCQB as AINMF and on the Frankfurt exchange as PF0. Shareholders are not required to take any action. Management said the TSX listing should enhance access to institutional investors and support commercial adoption of NetraAI.